About Rockwell Medical, Inc. - Common Stock (RMTI)
Rockwell Medical is a biopharmaceutical company that focuses on developing and providing innovative treatments for patients with chronic kidney disease and end-stage renal disease. The company specializes in therapies aimed at addressing the complications associated with these conditions, particularly iron deficiency anemia. Rockwell Medical is engaged in the research and development of solutions that enhance the quality of life for patients undergoing dialysis and other renal care, aiming to improve patient outcomes through effective medical interventions. Read More
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that Brian Cox has joined the Company as Vice President, Quality and Regulatory Compliance.
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the second quarter ended June 30, 2026 on Thursday, August 13, 2026. The Company will issue a press release at 6:00 a.m. ET followed by a live webcast at 8:00 a.m. ET.
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that its Board of Directors (the "Board") has authorized a 1-for-10 reverse split of the Company's issued and outstanding common stock (the "Reverse Stock Split"). The Board received approval at the Company's Annual Meeting of Stockholders on June 12, 2026 to approve and adopt an amendment to the Company's Certificate of Incorporation to effect a reverse stock split of the Company's common stock.
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company has renewed and extended its product purchase agreement (the "Agreement") with aQua Dialysis, LLP, a leading independent provider of in-center hemodialysis and home dialysis services in Texas.
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company entered into a three-year product purchase agreement (the "Agreement") with Heritage Dialysis, a Michigan-based family-owned company comprised of dialysis professionals that specialize in providing home dialysis in skilled nursing facilities, assisted living and senior living communities, and patients' homes.
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three months ended March 31, 2026.
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the first quarter ended March 31, 2026 on Thursday, May 7, 2026. The Company will issue a press release at 6:00am ET followed by a live webcast at 8:00am ET.
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three and twelve months ended December 31, 2025.
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the fourth quarter and full-year ended December 31, 2025 on Thursday, March 26, 2026. The Company will issue a press release at 6:00am ET followed by a live webcast at 8:00am ET.
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company has been certified as a Great Place to Work® for the fourth year in a row.
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced preliminary unaudited financial results for the three months and twelve months ended December 31, 2025.
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company has added 30 new customers in the western portion of the United States.
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Amended and Restated Product Purchase Agreement (the "Amended Agreement") dated September 18, 2023 between the Company and one of the largest dialysis providers in the United States (the "Customer") has been extended through December 31, 2026. As part of the Amended Agreement, product pricing will be increased for the extended term.
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company appointed Joe Dawson to its board of directors. Additionally, Andrea Heslin Smiley has resigned from the Company's board of directors to pursue other endeavors.
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three and nine months ended September 30, 2025.
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that Rashad Brown has joined the Company as Vice President, Manufacturing and Supply Chain. Mr. Brown brings more than two decades of leadership experience in manufacturing operations, procurement, warehouse management, and supply chain optimization within regulated healthcare manufacturing environments.
